Press Release Description

Growing Prevalence of Cardiovascular Disease Anticipated to Proliferate the Global Dyslipidemia Market Growth

The Global Dyslipidemia market is projected to proliferate the at an exponential rate on an account of rising prevalence of cardiovascular diseases (CVD) among the populace and high prevalent population of dyslipidemia patients. In addition, rapidly increasing cholesterol abnormalities in developed economies such as North America and Europe and lipid lowering drugs in the emerging countries such as India and China. Apart from this, launch of new drugs in the market and extensive funding toward the research and development of novel drugs are anticipated to promulgate the growth of Dyslipidemia market in the forecast period.

According to MarkNtel Advisors’ research report titled Global Dyslipidemia Market Analysis, 2020”, the Global Dyslipidemia market is anticipated to grow at a CAGR of around 10% during 2020-25. Based on type, drug segment acquired the lion’s share in the Global Dyslipidemia market in 2019. Statins dominated the drug segment market due to a surging usage of statins drugs to reduce the risk of CVDs along with a boost in the demand for statin drugs such as Lipitor and Crestor to reduce bad cholesterol levels in the body.

Moreover, omega-3 fatty acid segment would also witness steady market growth in the coming years. The growing patient inclination toward the use of omega-3 fatty acid derivatives for treating hypertriglyceridemia that is developed due to uncontrolled diabetes which could further lead to dyslipidemia. Hence, these factors are expected to stimulate the growth of this segment in the near future.

“Global Dyslipidemia Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for Dyslipidemia providers across the globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.       

North America Captured the Lion’s Share
North America captured the largest market share in Global Dyslipidemia market in 2019. United States dominated the North America Dyslipidemia market owing to the growing healthcare concerns about the treatment of dyslipidemia and rising rate of abnormal cholesterol levels among people. In 2015–2016, more than 12% of adults age 20 and older had total cholesterol higher than 240 mg/dL, and more than 18% had high-density lipoprotein cholesterol levels less than 40 mg/dL in the country. Moreover, the soaring presence of patented dyslipidemia formulations in the country is anticipated to accelerate the growth of Dyslipidemia market in the region in the forthcoming period as stated in MarkNtel Advisors’ research report “Global Dyslipidemia Market Analysis, 2020”.  

According to MarkNtel Advisors, the key players with a considerable market share in the Global Dyslipidemia market are Merck, Pfizer, Sanofi, Bristol-Myers Squibb, Abionyx (Cerenis), Cipla, Daewoong Pharmaceutical, Daiichi Sankyo, Novartis, Amgen etc.

 Market Segmentation:
1.    By Type (Diagnosis & Monitoring Test, Drugs (Statin Drugs [High-intensity, Moderate-intensity, Low-intensity), Non-Statin Drugs, [Cholesterol Absorption Inhibitors, Bile Acid Sequesterants {Cholestyramine, Colesevelam, Cholybar, Colestipol}, Fibric Acid Derivatives, Niacins, PCSK9 inhibitors, Supplements of omega-3 fats]))
2.    By End-User (Clinics, Hospitals & Specialty Centers, Medical Laboratories, Others)
3.    By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
4.    By Country (US, Canada, Mexico, Brazil, UK, Germany, France, Spain, Italy, The Netherlands, Russia, China, Japan, South Korea, India, South East-Asia, Australia, UAE, Saudi Arabia, Egypt, Turkey, Nigeria, Israel, South Africa), 
5.    By Company (Merck, Pfizer, Sanofi, Bristol-Myers Squibb, Abionyx (Cerenis), Cipla, Daewoong Pharmaceutical, Daiichi Sankyo, Novartis, Amgen etc.)

Key questions answered in the study: 
1.    What are the current and future trends of the Dyslipidemia industry? 
2.    How the industry has been evolving in terms of end-user demand and application areas?
3.    How the competition has been shaping across the countries followed by their comparative factorial indexing?
4.    What are the key growth drivers and challenges for the Dyslipidemia industry?
5.    What is the customer orientation, purchase behavior, and expectations from the Dyslipidemia firms across various regions?